Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394853 | 1.00 | DRD2 (0.38) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL1394110 | 1.00 | DRD2 (0.38) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL3970694 | 0.82 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL5860445 | 0.82 | — | — | |
| SCHEMBL13833151 | 0.82 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL17996818 | 0.82 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL636364 | 0.82 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL8860654 | 0.82 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ABRD4 | |
| SCHEMBL654972 | 0.80 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL25299343 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370446-B1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-B]PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES,PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-11-25 | — | — | EP | claimed |
| US-8546395-B2 | 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| CN-101522661-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (VG) | 2009-09-02 | — | — | CN | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3897839-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8546395-B2 | 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-4616015-A | HYPOTENSIVE AGENT, ANTULCER AGENT, ANTICOAGULANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0122627-A2 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-24 | — | — | EP | disclosed |
| US-3970647-A | Bis-(triazinylamino)stilbene compounds | SANDOZ LTD. (CH) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | DRD2 2282/4885DRD3 1614/4885MEN1 856/4885 |
| US-20120010208-A1 | 6-CYCLOAMINO-3-(1H-PYRROLO[2,3-b]PYRIDIN-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CBR1, CNR1 | DRD2 356/4885DRD3 254/4885MEN1 2013/4885 |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | DRD2 3905/4885DRD3 4492/4885MEN1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.